Trial Profile
Collection of Long-Term Outcome Data for Subjects Who Have Previously Participated in Selected Ipilimumab (MDX-010) Studies in Metastatic Melanoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jun 2010
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Medarex
- 16 Jan 2010 Long-term results for 64 patients enrolled on MDX010-08 have been published online in Investigational New Drugs in conjunction with results of the original protocol.
- 08 Oct 2009 Actual patient number (160) added as reported by ClinicalTrials.gov.
- 29 Jun 2009 New trial record